626. The Efficacy and Safety of Maintenance with Doravirine Plus Two NRTIs after Initial Suppression in Adults with HIV-1 in the DRIVE-FORWARD Clinical Trial: Results from the Study Extension through 192 Weeks

BACKGROUND: DRIVE-FORWARD is a phase 3 trial with a completed double-blind period comparing doravirine (DOR) 100 mg with ritonavir-boosted darunavir (DRV/r) 800/100 mg, both administered with two nucleos(t)ide reverse transcriptase inhibitors (NRTIs; tenofovir and emtricitabine, or abacavir and lami...

Descripción completa

Detalles Bibliográficos
Autores principales: Cahn, Pedro, Molina, Jean-michel, Lombaard, Johan, Squires, Kathleen, Kumar, Sushma, Wan, Hong, Teal, Valerie, Asante-Appiah, Ernest, Sklar, Peter, Martin, Elizabeth A, Lahoulou, Rima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644615/
http://dx.doi.org/10.1093/ofid/ofab466.824

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644615/
http://dx.doi.org/10.1093/ofid/ofab466.824

Ejemplares similares